Inactivation of Rv2525c, a Substrate of the Twin Arginine Translocation (Tat) System of Mycobacterium tuberculosis, Increases -Lactam Susceptibility and Virulence
Saint-Joanis, Brigitte Demangel, Caroline Jackson, Mary Brodin, Priscille Marsollier, Laurent Boshoff, Helena Cole, Stewart T.
Journal of Bacteriology, 2006
https://doi.org/10.1128/jb.00631-06
Mary Jackson
Jackson Mary
ORCID: 0000-0002-9212-0258
Analysis of uracil phosphoribosyltransferase expression in Mycobacterium tuberculosis and evaluation of upp knockout strain in infected mice 10.1093/femsle/fnx023
Biosynthesis of the Methylthioxylose Capping Motif of Lipoarabinomannan in Mycobacterium tuberculosis. 10.1021/acschembio.6b01071
Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro. 10.1128/AAC.02399-16
Assembling of the Mycobacterium tuberculosis Cell Wall Core 10.1074/jbc.M116.739227
Identification of a Novel Mycobacterial Arabinosyltransferase Activity Which Adds an Arabinosyl Residue to alpha-D-Mannosyl Residues 10.1021/acschembio.6b00093
Metabolic profile of Mycobacterium smegmatis reveals Mce4 proteins are relevant for cell wall lipid homeostasis 10.1007/s11306-016-1035-4
Structural basis for selective recognition of acyl chains by the membrane-associated acyltransferase PatA 10.1038/ncomms10906
Structure-Function Profile of MmpL3, the Essential Mycolic Acid Transporter from Mycobacterium tuberculosis 10.1021/acsinfecdis.6b00095
Synthesis and evaluation of new 2-aminothiophenes against Mycobacterium tuberculosis 10.1039/c6ob00821f
Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3 10.1128/AAC.00826-16
A glycomic approach reveals a new mycobacterial polysaccharide 10.1093/glycob/cwv061
Covalent Modification of the Mycobacterium tuberculosis FAS-II Dehydratase by Isoxyl and Thiacetazone 10.1021/id500032q
CpsA, a LytR-CpsA-Psr Family Protein in Mycobacterium marinum, Is Required for Cell Wall Integrity and Virulence 10.1128/IAI.03081-14
Draft Genome Sequence of Mycobacterium chelonae Type Strain ATCC 35752 10.1128/genomeA.00536-15
Partial Saturation of Menaquinone in Mycobacterium tuberculosis: Function and Essentiality of a Novel Reductase, MenJ 10.1021/acscentsci.5b00212
The presence of a galactosamine substituent on the arabinogalactan of Mycobacterium tuberculosis abrogates full maturation of human peripheral blood monocyte-derived dendritic cells and increases secretion of IL-10 10.1016/j.tube.2015.04.002
A Noncompetitive Inhibitor for Mycobacterium tuberculosis's Class IIa Fructose 1,6-Bisphosphate Aldolase 10.1021/bi401022b
A Single Arabinan Chain Is Attached to the Phosphatidylinositol Mannosyl Core of the Major Immunomodulatory Mycobacterial Cell Envelope Glycoconjugate, Lipoarabinomannan 10.1074/jbc.M114.599415
Analysis of a panel of rapidly growing mycobacteria for resistance to aldehyde-based disinfectants 10.1016/j.ajic.2014.05.014
Biosynthesis and Translocation of Unsulfated Acyltrehaloses in Mycobacterium tuberculosis 10.1074/jbc.M114.581199
Gene Replacement in Mycobacterium chelonae: Application to the Construction of Porin Knock-Out Mutants 10.1371/journal.pone.0094951
Genetics of Capsular Polysaccharides and Cell Envelope (Glyco)lipids 10.1128/microbiolspec.MGM2-0021-2013
High-level Relatedness among Mycobacterium abscessus subsp massiliense Strains from Widely Separated Outbreaks 10.3201/eid2003.131106
Inactivation of Fructose-1,6-Bisphosphate Aldolase Prevents Optimal Co-catabolism of Glycolytic and Gluconeogenic Carbon Substrates in Mycobacterium tuberculosis 10.1371/journal.ppat.1004144
Long-term Survival and Virulence of Mycobacterium leprae in Amoebal Cysts 10.1371/journal.pntd.0003405
LprG-Mediated Surface Expression of Lipoarabinomannan Is Essential for Virulence of Mycobacterium tuberculosis 10.1371/journal.ppat.1004376
Mycobacterium tuberculosis Lipoprotein LprG Binds Lipoarabinomannan and Determines Its Cell Envelope Localization to Control Phagolysosomal Fusion 10.1371/journal.ppat.1004471
Novel Insights into the Mechanism of Inhibition of MmpL3, a Target of Multiple Pharmacophores in Mycobacterium tuberculosis 10.1128/AAC.03229-14
Purification and characterization of the acyltransferase involved in biosynthesis of the major mycobacterial cell envelope glycolipid - Monoacylated phosphatidylinositol dimannoside 10.1016/j.pep.2014.04.014
RND transporters protect Corynebacterium glutamicum from antibiotics by assembling the outer membrane 10.1002/mbo3.182
Role of the Mce1 transporter in the lipid homeostasis of Mycobacterium tuberculosis 10.1016/j.tube.2013.12.005
Structure-function relationships of membrane-associated GT-B glycosyltransferases 10.1093/glycob/cwt101
The cell envelope glycoconjugates of Mycobacterium tuberculosis 10.3109/10409238.2014.925420
The Mycobacterial Cell Envelope-Lipids 10.1101/cshperspect.a021105
Bacterial protein-O-mannosylating enzyme is crucial for virulence of Mycobacterium tuberculosis 10.1073/pnas.1219704110
Cooccurrence of Free-Living Amoebae and Nontuberculous Mycobacteria in Hospital Water Networks, and Preferential Growth of Mycobacterium avium in Acanthamoeba lenticulata 10.1128/AEM.03823-12
Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties 10.1016/j.bmc.2013.02.028
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis 10.1038/nm.3262
Genome Sequence of an Epidemic Isolate of Mycobacterium abscessus subsp. bolletii from Rio de Janeiro, Brazil 10.1128/genomeA.00617-13
Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen 10.1038/ncomms3748
Phylogenomics of Brazilian epidemic isolates of Mycobacterium abscessus subsp bolletii reveals relationships of global outbreak strains 10.1016/j.meegid.2013.09.012
Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis 10.2217/fmb.13.52
Regulation of Mycolactone, the Mycobacterium ulcerans Toxin, Depends on Nutrient Source 10.1371/journal.pntd.0002502
Subfractionation and analysis of the cell envelope (lipo)polysaccharides of Mycobacterium tuberculosis. 10.1007/978-1-62703-245-2_19
Updating and curating metabolic pathways of TB 10.1016/j.tube.2012.11.001
A Common Mechanism of Inhibition of the Mycobacterium tuberculosis Mycolic Acid Biosynthetic Pathway by Isoxyl and Thiacetazone 10.1074/jbc.M112.400994
A Small Multidrug Resistance-like Transporter Involved in the Arabinosylation of Arabinogalactan and Lipoarabinomannan in Mycobacteria 10.1074/jbc.M112.400986
Aldehyde-resistant mycobacteria bacteria associated with the use of endoscope reprocessing systems 10.1016/j.ajic.2011.11.004
Impact of the deletion of the six mce operons in Mycobacterium smegmatis 10.1016/j.micinf.2012.01.007
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane 10.1038/NCHEMBIO.794
Mechanistic Insights into the Retaining Glucosyl-3-phosphoglycerate Synthase from Mycobacteria 10.1074/jbc.M112.368191
Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability 10.1016/j.bmc.2012.03.058
Glycolytic and Non-glycolytic Functions of Mycobacterium tuberculosis Fructose-1,6-bisphosphate Aldolase, an Essential Enzyme Produced by Replicating and Non-replicating Bacilli 10.1074/jbc.M111.259440
Increased Virulence of an Epidemic Strain of Mycobacterium massiliense in Mice 10.1371/journal.pone.0024726
Investigation of ABC transporter from mycobacterial arabinogalactan biosynthetic cluster 10.4149/gpb_2011_03_239
Reconstitution of Functional Mycobacterial Arabinosyltransferase AftC Proteoliposome and Assessment of Decaprenylphosphorylarabinose Analogues as Arabinofuranosyl Donors 10.1021/cb200091m
The structure-activity relationship of urea derivatives as anti-tuberculosis agents 10.1016/j.bmc.2011.07.034
An Oligopeptide Transporter of Mycobacterium tuberculosis Regulates Cytokine Release and Apoptosis of Infected Macrophages 10.1371/journal.pone.0012225
Biosynthetic Origin of the Galactosamine Substituent of Arabinogalactan in Mycobacterium tuberculosis 10.1074/jbc.M110.188110
Molecular Basis of Phosphatidyl-myo-inositol Mannoside Biosynthesis and Regulation in Mycobacteria 10.1074/jbc.R110.168328
Rational Design, Synthesis, and Evaluation of New Selective Inhibitors of Microbial Class II (Zinc Dependent) Fructose Bis-phosphate Aldolases 10.1021/jm1009814
Synthesis, biological activity, and evaluation of the mode of action of novel antitubercular benzofurobenzopyrans substituted on A ring 10.1016/j.ejmech.2010.09.048
AftD, a novel essential arabinofuranosyltransferase from mycobacteria 10.1093/glycob/cwp116
Chapter 2: Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis. 10.1016/S0065-2164(09)69002-X
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645
Identification of a Polyprenylphosphomannosyl Synthase Involved in the Synthesis of Mycobacterial Mannosides 10.1128/JB.00431-09
Initiation of Methylglucose Lipopolysaccharide Biosynthesis in Mycobacteria 10.1371/journal.pone.0005447
Mce3R, a TetR-type transcriptional repressor, controls the expression of a regulon involved in lipid metabolism in Mycobacterium tuberculosis 10.1099/mic.0.027086-0
New Insights into the Early Steps of Phosphatidylinositol Mannoside Biosynthesis in Mycobacteria PimB' IS AN ESSENTIAL ENZYME OF MYCOBACTERIUM SMEGMATIS 10.1074/jbc.M109.030593
Polymethylated Polysaccharides from Mycobacterium Species Revisited 10.1074/jbc.R800047200
Role of Porins in the Susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to Aldehyde-Based Disinfectants and Drugs 10.1128/AAC.00590-09
Substrate-induced Conformational Changes in the Essential Peripheral Membrane-associated Mannosyltransferase PimA from Mycobacteria IMPLICATIONS FOR CATALYSIS 10.1074/jbc.M109.003947
A point mutation in the two-component regulator PhoP-PhoR accounts for the absence of polyketide-derived acyltrehaloses but not that of phthiocerol dimycocerosates in Mycobacterium tuberculosis H37Ra 10.1128/JB.01465-07
Capsular glucan and intracellular glycogen of Mycobacterium tuberculosis: biosynthesis and impact on the persistence in mice 10.1111/j.1365-2958.2008.06445.x
Lipoarabinomannan of Mycobacterium: Mannose capping by a multifunctional terminal mannosyltransferase 10.1073/pnas.0807761105
N-D-Aldopentofuranosyl-N '-[p-(isoamyloxy)phenyl]-thiourea derivatives: Potential anti-TB therapeutic agents 10.1016/j.bmcl.2008.03.033
Preliminary crystallographic analysis of GpgS, a key glucosyltransferase involved in methylglucose lipopolysaccharide biosynthesis in Mycobacterium tuberculosis 10.1107/S1744309108032892
Synthesis and biochemical evaluation of selective inhibitors of class II fructose bisphosphate aldolases: towards new synthetic antibiotics 10.1002/chem.200800857
The immunomodulatory lipoglycans, lipoarabinomannan and lipomannan, are exposed at the mycobacterial cell surface 10.1016/j.tube.2008.04.002
Genetic basis for the biosynthesis of methylglucose lipopolysaccharides in Mycobacterium tuberculosis 10.1074/jbc.M702676200
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis 10.1128/AAC.00433-07
Long-chain multiple methyl-branched fatty acid-containing lipids of Mycobacterium tuberculosis: Biosynthesis, transport, regulation and biological activities 10.1016/j.tube.2006.05.003
Molecular recognition and interfacial catalysis by the essential phosphatidylinositol mannosyltransferase PimA from mycobacteria 10.1074/jbc.M702087200
New insights into the biosynthesis of mycobacterial lipomannan arising from deletion of a conserved gene 10.1074/jbc.M703389200
Signature-tagged transposon mutagenesis identifies novel Mycobacterium tuberculosis genes involved in the parasitism of human macrophages 10.1128/IAI.00058-06
The glycosyltransferases of Mycobacterium tuberculosis - roles in the synthesis of arabinogalaetan, lipoarahinolrnlannan, and other glyeoeonjugates 10.1093/glycob/cwm010
Biosynthesis of mycobacterial lipoarabinomannan: Role of a branching mannosyltransferase 10.1073/pnas.0603049103
Comparative investigation of the pathogenicity of three Mycobacterium tuberculosis mutants defective in the synthesis of p-hydroxybenzoic acid derivatives 10.1016/j.micinf.2006.04.008
Inactivation of Rv2525c, a Substrate of the Twin Arginine Translocation (Tat) System of Mycobacterium tuberculosis, Increases -Lactam Susceptibility and Virulence 10.1128/JB.00631-06
LppX is a lipoprotein required for the translocation of phthiocerol dimycocerosates to the surface of Mycobacterium tuberculosis 10.1038/sj.emboj.7601048
The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth 10.1128/JB.00963-06
The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria 10.1016/j.febslet.2006.04.046
The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis 10.1074/jbc.C500388200
Crystallization and preliminary crystallographic analysis of PimA, an essential mannosyltransferase from Mycobacterium smegmatis 10.1107/S1744309105012364
Deciphering the molecular bases of Mycobacterium tuberculosis binding to the lectin DC-SIGN reveals an underestimated complexity 10.1042/BJ20050709
p-Hydroxybenzoic acid synthesis in Mycobacterium tuberculosis 10.1074/jbc.M508332200
Reduced local growth and spread but preserved pathogenicity of a DeltapurC Mycobacterium tuberculosis auxotrophic mutant in gamma interferon receptor-deficient mice after aerosol infection 10.1128/IAI.73.1.666-670.2005
Production of phthiocerol dimycocerosates protects Mycobacterium tuberculosis from the cidal activity of reactive nitrogen intermediates produced by macrophages and modulates the early immune response to infection 10.1046/j.1462-5822.2004.00368.x
Taxonomic characterization of nine strains isolated from clinical and environmental specimens, and proposal of Corynebacterium tuberculostearicum sp nov. 10.1099/ijs.0.02907-0
DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells 10.1084/jem.20021468
Deficiency in mycolipenate- and mycosanoate-derived acyltrehaloses enhances early interactions of Mycobacterium tuberculosis with host cells 10.1046/j.1462-5822.2003.00289.x
Identification of the required acyltransferase step in the biosynthesis of the phosphatidylinositol mannosides of Mycobacterium species 10.1074/jbc.M303639200
Sulfolipid deficiency does not affect the virulence of Mycobacterium tuberculosis H37Rv in mice and guinea pigs 10.1128/IAI.71.8.4684-4690.2003
The cell surface receptor DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan 10.1074/jbc.C200586200
Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis 10.1074/jbc.M311209200
Virulence attenuation of two Mas-like polyketide synthase mutants of Mycobacterium tuberculosis 10.1099/mic.0.26278-0
Definition of the first mannosylation step in phosphatidylinositol mannoside synthesis - PimA is essential for growth of mycobacteria 10.1074/jbc.M204060200
Phospholipases C are involved in the virulence of Mycobacterium tuberculosis 10.1046/j.1365-2958.2002.03009.x
Transient requirement of the PrrA-PrrB two-component system for early intracellular multiplication of Mycobacterium tuberculosis 10.1128/IAI.70.5.2256-2263.2002
Cell wall core galactofuran synthesis is essential for growth of mycobacteria 10.1128/JB.183.13.3991-3998.2001
Phosphatidylinositol is an essential phospholipid of mycobacteria 10.1074/jbc.M004658200
Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope 10.1046/j.1365-2958.1999.01310.x
Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis 10.1073/pnas.94.20.10955
Disinfectant Susceptibility Profiling of Glutaraldehyde-Resistant Nontuberculous Mycobacteria 10.1017/ice.2017.75
Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity 10.1016/j.bmc.2017.05.015
Mycobacterium bovis hosted by free-living-amoebae permits their long-term persistence survival outside of host mammalian cells and remain capable of transmitting disease to mice 10.1111/1462-2920.13810
Green Fluorescent Protein as a protein localization and topological reporter in mycobacteria 10.1016/j.tube.2017.04.001
2-aminoimidazoles potentiate ß-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ß-lactamase secretion and increasing cell envelope permeability 10.1371/journal.pone.0180925
HLA-E Presents Glycopeptides from the Mycobacterium tuberculosis Protein MPT32 to Human CD8(+) T cells 10.1038/s41598-017-04894-0
Mycobacterium talmoniae sp. nov., a slowly growing mycobacterium isolated from human respiratory samples 10.1099/ijsem.0.001998
Mycobacterium tuberculosis is protected from NADPH oxidase and LC3-associated phagocytosis by the LCP protein CpsA 10.1073/pnas.1707792114
Yersinia pestis Survival and Replication in Potential Ameba Reservoir 10.3201/eid2402.171065
Covalent modifications of polysaccharides in mycobacteria 10.1038/nchembio.2571
Impact of the epoxide hydrolase EphD on the metabolism of mycolic acids in mycobacteria 10.1074/jbc.RA117.000246
Cytokinin Signaling in Mycobacterium tuberculosis 10.1128/mBio.00989-18
Evidence of zoonotic leprosy in Pará, Brazilian Amazon, and risks associated with human contact or consumption of armadillos 10.1371/journal.pntd.0006532
Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent 10.3389/fmicb.2018.02231
Advancing Translational Science for Pulmonary NTM Infections: A Roadmap for Research. 10.1164/rccm.201807-1273PP
Deciphering the molecular basis of mycobacteria and lipoglycan recognition by the C-type lectin Dectin-2 10.1038/s41598-018-35393-5
Disruption of the SucT acyltransferase in Mycobacterium smegmatis abrogates succinylation of cell envelope polysaccharides 10.1074/jbc.ra119.008585
Direct Inhibition of MmpL3 by Novel Antitubercular Compounds 10.1021/acsinfecdis.9b00048
Characterization of Arabinosyl Transfer Reactions in the Biosynthesis of Mycobacterial Cell Envelope (Lipo)Polysaccharides 10.1007/978-1-4939-9154-9_14
2-aminoimidazoles collapse mycobacterial proton motive force and block the electron transport chain 10.1038/s41598-018-38064-7
Indole-2-Carboxamides Are Active against Mycobacterium abscessus in a Mouse Model of Acute Infection 10.1128/aac.02245-18
Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis 10.3389/fmicb.2018.01895
The MmpL3 interactome reveals a complex crosstalk between cell envelope biosynthesis and cell elongation and division in mycobacteria 10.1038/S41598-019-47159-8
New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics 10.2174/1381612819666131118203641
Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy 10.1590/S0074-02762012000900014
Structure, Biosynthesis, and Activities of the Phosphatidyl-myo-Inositol-Based Lipoglycans 10.1128/9781555815783.CH6
The Mycobacterium tuberculosis purine biosynthetic pathway: Isolation and characterization of the purC and purL genes 10.1099/00221287-142-9-2439
MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections 10.3389/FMICB.2018.01547
Mycobacterium tuberculosis Des protein: An immunodominant target for the humoral response of tuberculous patients 10.1128/IAI.65.7.2883-2889.1997
Interactions of free-living amoebae with rice bacterial pathogens Xanthomonas oryzae pathovars oryzae and oryzicola 10.1371/JOURNAL.PONE.0202941
Mobile genetic elements and plasmids: tools for genetic studies 10.1002/9781444311433.CH2
Biochemical and microbiological evaluation of N-aryl urea derivatives against mycobacteria and mycobacterial hydrolases 10.1039/C9MD00122K
Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance 10.1128/AAC.00547-19
Mechanisms of Resistance Associated with the Inhibition of the Dehydration Step of Type II Fatty Acid Synthase in Mycobacterium tuberculosis 10.1021/ACSINFECDIS.9B00162
Interactions of free-living amoebae with the rice fungal pathogen, Rhizoctonia solani 10.1186/S13104-019-4802-2
Analysing nonsynonymous mutations between two Mycobacterium bovis strains with contrasting pathogenic profiles 10.1016/J.VETMIC.2019.108482
Cloning and Partial Characterization of an Endo-alpha-(1 -> 6)-D-Mannanase Gene from Bacillus circulans 10.3390/IJMS20246244
Efficient method for targeted gene disruption by homologous recombination in Mycobacterium avium subspecie paratuberculosis 10.1016/J.RESMIC.2020.04.001
Busting biofilms: free-living amoebae disrupt preformed methicillin-resistant Staphylococcus aureus (MRSA) and Mycobacterium bovis biofilms 10.1099/MIC.0.000933
Potency Increase of Spiroketal Analogs of Membrane Inserting Indolyl Mannich Base Antimycobacterials Is Due to Acquisition of MmpL3 Inhibition 10.1021/ACSINFECDIS.0C00121
Cell Surface Remodeling of Mycobacterium abscessus under Cystic Fibrosis Airway Growth Conditions 10.1021/ACSINFECDIS.0C00214
Polysaccharide Succinylation Enhances the Intracellular Survival of Mycobacterium abscessus 10.1021/ACSINFECDIS.0C00361
Fragment-based discovery of a new class of inhibitors targeting mycobacterial tRNA modification 10.1093/NAR/GKAA539
Secondary extended mannan side chains and attachment of the arabinan in mycobacterial lipoarabinomannan 10.1038/S42004-020-00356-3
MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections 10.3390/IJMS21176202
Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System 10.1128/AAC.01914-20
Transporters Involved in the Biogenesis and Functionalization of the Mycobacterial Cell Envelope 10.1021/ACS.CHEMREV.0C00869
Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis 10.1021/ACSINFECDIS.0C00675
Use of Synthetic Glycolipids to Probe the Number and Position of Arabinan Chains on Mycobacterial Arabinogalactan 10.1021/ACSCHEMBIO.0C00765
A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in Mycobacterium tuberculosis 10.1021/ACSINFECDIS.0C00325
Mycobacterial Epoxide Hydrolase EphD Is Inhibited by Urea and Thiourea Derivatives 10.3390/IJMS22062884
Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities 10.1002/MED.21798
Role of PhoPR in the response to stress of Mycobacterium bovis 10.1016/J.CIMID.2020.101593
Stepwise pathogenic evolution of Mycobacterium abscessus 10.1126/SCIENCE.ABB8699
Identification and functional analysis of a galactosyltransferase capable of cholesterol glycolipid formation in the Lyme disease spirochete Borrelia burgdorferi 10.1371/JOURNAL.PONE.0252214
A Model of action for peripheral Membrane-Associated GT-B Glycosyltransferases 10.1107/S010876731108799X
Structural basis of methylglucose lipopolysaccharide biosynthesis in mycobacteria 10.1107/S0108767311080019
Transcriptional adaptation of Mycobacterium ulcerans in an original mouse model: New insights into the regulation of mycolactone 10.1080/21505594.2021.1929749
Increased Virulence of Outer Membrane Porin Mutants of Mycobacterium abscessus 10.3389/FMICB.2021.706207
Identifying Bacterial and Host Factors Involved in the Interaction of Mycobacterium bovis with the Bovine Innate Immune Cells 10.3389/FIMMU.2021.674643
An antitubercular prodrug leaves Mycobacterium tuberculosis facing a difficult choice, poisoning or starvation? 10.1016/J.CHEMBIOL.2021.07.019
S16 and T18 mannosylation sites of LppX are not essential for its activity in phthiocerol dimycocerosates localization at the surface of Mycobacterium tuberculosis 10.1016/J.RESMIC.2021.103874
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a
High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Worms' Antimicrobial Peptides. 10.3390/md17090512
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570
Cell microbiology interview 10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505
Nathalie deboosere
deboosere Nathalie
ORCID: 0000-0002-2873-5485
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. 10.3390/toxins9070227
Phenotypic assays for Mycobacterium tuberculosis infection. 10.1002/cyto.a.23129
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. 10.1021/acschembio.7b00091
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114
Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces. 10.1016/j.fm.2012.04.007
Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR. 10.1016/j.jviromet.2011.10.013
Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce. 10.1016/j.ijfoodmicro.2011.08.011
Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens. 10.1016/j.jviromet.2011.06.002
Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water. 10.1128/aem.02484-10
A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries. 10.1016/j.fm.2010.05.018
Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment. 10.1016/j.watres.2010.01.013
Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables. 10.1016/j.ijfoodmicro.2005.11.007
Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system. 10.1016/j.ijfoodmicro.2003.10.015
Host-pathogen systems for early drug discovery against tuberculosis. 10.1016/j.mib.2017.11.017
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. 10.1073/pnas.1707840114
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. 10.1038/s41598-017-11843-4
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages. 10.1016/j.chom.2017.07.020
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-017-05453-3
Host-directed therapies offer novel opportunities for the fight against tuberculosis. 10.1016/j.drudis.2017.05.005
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs. 10.1016/j.ijpharm.2017.05.030
Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. 10.3389/fcimb.2017.00137
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. 10.2217/nnm-2016-0364
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. 10.1126/science.aag1006
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. 10.1007/s00401-016-1652-z
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. 10.1016/j.str.2016.07.009
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. 10.1007/s00705-016-2771-5
[Mycolactone: the amazing analgesic mycobacterial toxin]. 10.1051/medsci/20163202007
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. 10.1039/c5ob02630j
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. 10.1128/jvi.01473-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083
Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. 10.1371/journal.ppat.1004650
[High content screening in chemical biology: overview and main challenges]. 10.1051/medsci/20153102016
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. 10.1007/978-1-4939-2450-9_24
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. 10.1021/cb5007163
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. 10.1128/aac.03705-14
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 10.1016/j.cell.2014.04.040
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. 10.1021/jm500422b
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262
The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. 10.1371/journal.pone.0047573
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200825u
A novel specific edge effect correction method for RNA interference screenings. 10.1093/bioinformatics/btr648
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. 10.1371/journal.pone.0026675
High-content screening in infectious diseases. 10.1016/j.cbpa.2011.05.023
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200076a
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. 10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. 10.4155/fmc.10.223
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ. 10.1099/mic.0.038133-0
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. 10.1371/journal.ppat.1000645
Systematic genetic nomenclature for type VII secretion systems. 10.1371/journal.ppat.1000507
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. 10.1016/j.biomaterials.2009.09.044
Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. 10.1126/science.1171583
Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure. 10.1177/1087057108328762
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. 10.1128/jb.00469-07
[Aquatic insects and transmission of Mycobacterium ulcerans]. 10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. 10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. 10.1371/journal.pmed.0040064
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. 10.1016/j.bmc.2006.12.009
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. 10.1128/jb.00631-06
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. 10.1128/iai.02086-05
Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. 10.1016/j.bmc.2006.03.033
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. 10.1128/iai.74.4.2128-2137.2006
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. 10.1128/iai.74.1.88-98.2006
Tuberculosis: from genome to vaccine. 10.1586/14760584.4.4.541
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity. 10.1074/jbc.m503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. 10.1099/mic.0.27799-0
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. 10.1086/421468
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. 10.1128/iai.72.4.2170-2176.2004
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex. 10.1099/mic.0.26662-0
CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. 10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. 10.1038/nm859
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. 10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. 10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. 10.1021/bi015732y
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483
Caroline Demangel
Demangel Caroline
ORCID: 0000-0001-7848-586X
Recombinant Antibodies against Mycolactone 10.3390/toxins11060346
Shaping mycolactone for therapeutic use against inflammatory disorders 10.1126/SCITRANSLMED.AAB0458
Synthetic Variants of Mycolactone Bind and Activate Wiskott-Aldrich Syndrome Proteins 10.1021/JM5008819
Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings 10.12968/JOWC.2014.23.8.417
Understanding Buruli Ulcer (Mycobacterium ulcerans Disease) 10.1128/9781555816803.CH12
Ipomoeassin F Binds Sec61 alpha to Inhibit Protein Translocation 10.1021/JACS.8B13506
Mycolactone subverts immunity by selectively blocking the Sec61 translocon 10.1084/JEM.20160662
Functional Analysis via Standardized Whole-Blood Stimulation Systems Defines the Boundaries of a Healthy Immune Response to Complex Stimuli 10.1016/J.IMMUNI.2014.03.002
Proteomic Analysis of the SH2Domain-containing Leukocyte Protein of 76 kDa (SLP76) Interactome 10.1074/MCP.M112.025908
Pathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens 10.1007/S00018-014-1561-Z
Buruli ulcer disease: prospects for a vaccine 10.1007/S00430-009-0109-6
Combined Inflammatory and Metabolic Defects Reflected by Reduced Serum Protein Levels in Patients with Buruli Ulcer Disease 10.1371/JOURNAL.PNTD.0002786
Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production 10.1002/1521-4141(200204)32:4<994::AID-IMMU994>3.3.CO;2-Y
Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans 10.1038/NRMICRO2077
Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring 10.1371/JOURNAL.PNTD.0001237
Molecular Mimicry between a Monoclonal Antibody and One Subunit of Crotoxin, a Heterodimeric Phospholipase A2 Neurotoxin 10.1515/BC.1999.071
Antigen Discovery: a Postgenomic Approach to Leprosy Diagnosis 10.1128/IAI.74.1.175-182.2006
Zika virus induces massive cytoplasmic vacuolization and paraptosis‐like death in infected cells 10.15252/EMBJ.201695597
Comparison of various methods for monitoring hybridoma cell proliferation 10.1016/0022-1759(90)90379-A
Immunosuppressive Signature of Cutaneous Mycobacterium ulcerans Infection in the Peripheral Blood of Patients with Buruli Ulcer Disease 10.1086/646615
Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer 10.1126/SCITRANSLMED.3003586
Mycobacterial Phenolic Gycolipids Selectively Disable TRIF-Dependent TLR4 Signaling in Macrophages 10.3389/FIMMU.2018.00002
A Diverted Total Synthesis of Mycolactone Analogues: An Insight into Buruli Ulcer Toxins 10.1002/CHEM.201102542
Mycobacterium leprae Phenolglycolipid-1 Expressed by Engineered M. bovis BCG Modulates Early Interaction with Human Phagocytes 10.1371/JOURNAL.PPAT.1001159
Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone 10.1084/JEM.20070234
Sec61 blockade by mycolactone inhibits antigen cross-presentation independently of endosome-to-cytosol export 10.1073/PNAS.1705242114
Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin 10.1111/J.1462-5822.2005.00546.X
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/IAI.72.4.2170-2176.2004
Mycolactone displays anti-inflammatory effects on the nervous system 10.1371/JOURNAL.PNTD.0006058
Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression 10.1073/PNAS.1016496108
A Novel Mycolactone Toxin Obtained by Biosynthetic Engineering 10.1002/CBIC.200700411
Targeting Dendritic Cells with Antigen-Containing Liposomes 10.1158/0008-5472.CAN-04-0138
Proteomics Reveals Scope of Mycolactone-mediated Sec61 Blockade and Distinctive Stress Signature 10.1074/MCP.RA118.000824
Dendritic cells infected with Mycobacterium bovis bacillus Calmette Guerin activate CD8(+) T cells with specificity for a novel mycobacterial epitope 10.1093/INTIMM/13.4.451
Modular total syntheses of mycolactone A/B and its [ 2 H]-isotopologue 10.1039/C7OB01943B
TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection 10.4049/JIMMUNOL.168.9.4620
Factors controlling cell proliferation and antibody production in mouse hybridoma cells: I. Influence of the amino acid supply 10.1002/BIT.260380602
Differential Effects of Prior Exposure to Environmental Mycobacteria on Vaccination with Mycobacterium bovis BCG or a Recombinant BCG Strain Expressing RD1 Antigens 10.1128/IAI.73.4.2190-2196.2005
Phage-displayed and soluble mouse scFv fragments neutralize rabies virus 10.1016/S0166-0934(97)00099-2
Towards an immunodiagnostic test for leprosy 10.1016/J.MICINF.2006.04.002
Interaction of dendritic cells with mycobacteria: Where the action starts 10.1046/J.1440-1711.2000.00935.X
Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation 10.1172/JCI66576
Stimulation of Dendritic Cells via CD40 Enhances Immune Responses to Mycobacterium tuberculosis Infection 10.1128/IAI.69.4.2456-2461.2001
Role of Metabolic Waste Products in the Control of Cell Proliferation and Antibody Production by Mouse Hybridoma Cells 10.1089/HYB.1992.11.311
Inactivation of Rv2525c, a Substrate of the Twin Arginine Translocation (Tat) System of Mycobacterium tuberculosis, Increases -Lactam Susceptibility and Virulence 10.1128/JB.00631-06
Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette Guerin-infected dendritic cells 10.1002/(SICI)1521-4141(199906)29:06<1972::AID-IMMU1972>3.3.CO;2-T
Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism 10.1099/0022-1317-82-8-1885
Mycolactone Suppresses T Cell Responsiveness by Altering Both Early Signaling and Posttranslational Events 10.4049/JIMMUNOL.0902854
Mycolactone Diffuses from Mycobacterium ulcerans–Infected Tissues and Targets Mononuclear Cells in Peripheral Blood and Lymphoid Organs 10.1371/JOURNAL.PNTD.0000325
Dissection of ESAT-6 System 1 of Mycobacterium tuberculosis and Impact on Immunogenicity and Virulence 10.1128/IAI.74.1.88-98.2006
Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541
Single chain antibody fragments for the selective targeting of antigens to dendritic cells 10.1016/J.MOLIMM.2004.09.034
Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses 10.1016/J.CELREP.2016.08.011
Lipids of Pathogenic Mycobacteria: Contributions to Virulence and Host Immune Suppression 10.1111/J.1865-1682.2009.01072.X
Biologically active human anti-crotoxin scFv isolated from a semi-synthetic phage library 10.1016/S1380-2933(97)00068-7
Combining phage display and molecular modeling to map the epitope of a neutralizing antitoxin antibody 10.1046/J.1432-1327.2000.01244.X
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/NM859
Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease 10.1038/SREP17693
Reproducing the immune response against the Plasmodium vivax merozoite surface protein 1 with mimotopes selected from a phage-displayed peptide library 10.1016/S0161-5890(96)00058-2
Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer 10.1016/J.MICINF.2006.03.009
Lactate dehydrogenase (LDH) activity of the number of dead cells in the medium of cultured eukaryotic cells as marker 10.1016/0168-1656(92)90158-6
Entrapment of Intracytosolic Bacteria by Septin Cage-like Structures 10.1016/J.CHOM.2010.10.009
Priming by DNA Immunization Augments Protective Efficacy of Mycobacterium bovis Bacille Calmette-Guerin against Tuberculosis 10.1128/IAI.69.6.4174-4176.2001
Proteomic Analysis of the SH2 Domain-containing Leukocyte Protein of 76 kDa (SLP76) Interactome in Resting and Activated Primary Mast Cells 10.1074/MCP.A112.025908
Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria 10.1039/B803101K
Pathogenic and immunosuppressive properties of mycobacterial phenolic glycolipids 10.1016/J.BIOCHI.2017.03.012
ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria 10.1111/J.1462-5822.2012.01799.X
Sec61 blockade by mycolactone: A central mechanism in Buruli ulcer disease 10.1111/BOC.201800030
HOST IMMUNOMODULATION BY MYCOLACTONE, THE MYCOBACTERIUM ULCERANS TOXIN 10.1016/J.TOXICON.2017.12.018
Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges 10.1073/PNAS.1714765115
Parallel derivation of isogenic human primed and naive induced pluripotent stem cells 10.1038/S41467-017-02107-W
Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors 10.1038/S41590-018-0049-7
Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines 10.1186/S13073-018-0568-8
Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis 10.1093/EMBOJ/19.7.1525
Marsollier Laurent
Laurent Marsollier
ORCID: 0000-0001-5497-5995
High antibody titres induced by protein subunit vaccines using Mycobacterium ulcerans antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice. 10.7717/peerj.9659
Genome-wide association study of Buruli ulcer in rural Benin highlights role of two LncRNAs and the autophagy pathway. 10.1038/s42003-020-0920-6
Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model. 10.1128/iai.00753-19
Senegal, a new potential endemic country for Buruli ulcer? 10.1016/j.ijid.2019.09.020
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls. 10.3390/toxins11090516
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters. 10.3389/fphar.2019.00378
Microdeletion on chromosome 8p23.1 in a familial form of severe Buruli ulcer. 10.1371/journal.pntd.0006429
The potent effect of mycolactone on lipid membranes. 10.1371/journal.ppat.1006814
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. 10.3390/toxins9070227
Mouse model of colonization of the digestive tract with Acinetobacter baumannii and subsequent pneumonia. 10.2217/fmb-2016-0203
Ecology and Feeding Habits Drive Infection of Water Bugs with Mycobacterium ulcerans. 10.1007/s10393-017-1228-y
Draft Genome Sequence of Mycobacterium ulcerans S4018 Isolated from a Patient with an Active Buruli Ulcer in Benin, Africa. 10.1128/genomea.00248-17
An Optimized Method for Extracting Bacterial RNA from Mouse Skin Tissue Colonized by Mycobacterium ulcerans. 10.3389/fmicb.2017.00512
Multiple Introductions and Recent Spread of the Emerging Human Pathogen Mycobacterium ulcerans across Africa. 10.1093/gbe/evx003
Deforestation-driven food-web collapse linked to emerging tropical infectious disease, Mycobacterium ulcerans. 10.1126/sciadv.1600387
Chitin promotes Mycobacterium ulcerans growth. 10.1093/femsec/fiw067
Molecular Species Delimitation and Morphology of Aquatic and Sub-Aquatic Bugs (Heteroptera) in Cameroon. 10.1371/journal.pone.0154905
FVB/N Mice Spontaneously Heal Ulcerative Lesions Induced by Mycobacterium ulcerans and Switch M. ulcerans into a Low Mycolactone Producer. 10.4049/jimmunol.1502194
[Mycolactone: the amazing analgesic mycobacterial toxin]. 10.1051/medsci/20163202007
Clinical Features of Spontaneous Partial Healing During Mycobacterium ulcerans Infection. 10.1093/ofid/ofw013
Seasonal Patterns of Buruli Ulcer Incidence, Central Africa, 2002-2012. 10.3201/eid2108.141336
Mycobacterium ulcerans dynamics in aquatic ecosystems are driven by a complex interplay of abiotic and biotic factors. 10.7554/elife.07616
Development of a dry-reagent-based qPCR to facilitate the diagnosis of Mycobacterium ulcerans infection in endemic countries. 10.1371/journal.pntd.0003606
Extrahuman epidemiology of Acinetobacter baumannii in Lebanon. 10.1128/aem.03824-14
Mycobacterium ulcerans disease (Buruli ulcer) in Mali: A new potential African endemic country. 10.2340/00015555-1942
Buruli ulcer in South Western Nigeria: a retrospective cohort study of patients treated in Benin. 10.1371/journal.pntd.0003443
[Detection of the IS2404 insertion sequence and ketoreductase produced by Mycobacterium ulcerans in the aquatic Heteroptera in the health districts of Dabou and Tiassalé in Côte d'Ivoire]. 10.1684/mst.2014.0363
Topography and land cover of watersheds predicts the distribution of the environmental pathogen Mycobacterium ulcerans in aquatic insects. 10.1371/journal.pntd.0003298
Defining and targeting high-risk populations in Buruli ulcer--authors' reply. 10.1016/s2214-109x(14)70312-2
Buruli ulcer acquired in Mali: a rare and atypical situation. 10.1016/j.tmaid.2014.09.009
Findings in patients from Benin with osteomyelitis and polymerase chain reaction-confirmed Mycobacterium ulcerans infection. 10.1093/cid/ciu584
HIV infection and Buruli ulcer in Africa. 10.1016/s1473-3099(14)70882-5
Clinical epidemiology of laboratory-confirmed Buruli ulcer in Benin: a cohort study. 10.1016/s2214-109x(14)70223-2
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 10.1016/j.cell.2014.04.040
A case of guilt by association: Water bug bite incriminated in M. ulcerans infection. 10.1016/j.ijmyco.2014.01.004
Buruli ulcer disease in Republic of the Congo. 10.3201/eid2006.131498
Mycobacterium ulcerans ecological dynamics and its association with freshwater ecosystems and aquatic communities: results from a 12-month environmental survey in Cameroon. 10.1371/journal.pntd.0002879
First detection of Mycobacterium ulcerans DNA in environmental samples from South America. 10.1371/journal.pntd.0002660
[Buruli ulcer: a dynamic transversal research model performed through the international network of Pasteur Institutes]. 10.1051/medsci/20132910021
Photodegradation of the Mycobacterium ulcerans toxin, mycolactones: considerations for handling and storage. 10.1371/journal.pone.0033600
Adequate wound care and use of bed nets as protective factors against Buruli Ulcer: results from a case control study in Cameroon. 10.1371/journal.pntd.0001392
Geographic expansion of Buruli ulcer disease, Cameroon. 10.3201/eid1703.091859
Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. 10.1093/cid/ciq072
Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. 10.1371/journal.pntd.0000872
Use of fine-needle aspiration for diagnosis of Mycobacterium ulcerans infection. 10.1128/jcm.00558-10
Buruli ulcer, Central African Republic. 10.3201/eid1604.090195
Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer. 10.1371/journal.pntd.0000553
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. 10.1371/journal.ppat.1000645
Buruli ulcer in long-term traveler to Senegal. 10.3201/eid1501.080123
Optimized method for preparation of DNA from pathogenic and environmental mycobacteria. 10.1128/aem.01358-08
Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv. 10.1074/jbc.m802115200
Comprehensive proteome analysis of Mycobacterium ulcerans and quantitative comparison of mycolactone biosynthesis. 10.1002/pmic.200701018
Risk factors for buruli ulcer: a case control study in Cameroon. 10.1371/journal.pntd.0000101
[Aquatic insects and transmission of Mycobacterium ulcerans]. 10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. 10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. 10.1371/journal.pmed.0040064
Early trafficking events of Mycobacterium ulcerans within Naucoris cimicoides. 10.1111/j.1462-5822.2006.00790.x
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. 10.1128/jb.00631-06
Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. 10.1016/j.micinf.2006.03.009
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. 10.1128/iai.74.1.88-98.2006
Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. 10.1111/j.1462-5822.2005.00546.x
Colonization of the salivary glands of Naucoris cimicoides by Mycobacterium ulcerans requires host plasmatocytes and a macrolide toxin, mycolactone. 10.1111/j.1462-5822.2005.00521.x
[Diagnosis of Mycobacterium ulcerans infections in French Guiana]. 10.1016/s0755-4982(04)98974-9
Aquatic snails, passive hosts of Mycobacterium ulcerans. 10.1128/aem.70.10.6296-6298.2004
Aquatic plants stimulate the growth of and biofilm formation by Mycobacterium ulcerans in axenic culture and harbor these bacteria in the environment. 10.1128/aem.70.2.1097-1103.2004
Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin. 10.1016/s0924-8579(03)00240-1
[Ecology and transmission of Mycobacterium ulcerans]. 10.1016/s0369-8114(03)00151-2
Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. 10.1128/aac.47.4.1228-1232.2003
Aquatic insects as a vector for Mycobacterium ulcerans. 10.1128/aem.68.9.4623-4628.2002
Summary of the Sussex-Huawei locomotion-transportation recognition challenge
Observation of a manifold in the chaotic phase space of an asymmetric optical microcavity
Localized temporal variation of Earth's inner-core boundary from high-quality waveform doublets
Off-axis multi-wavelength dispersion controlling metalens for multi-color imaging
Impact of United States political sanctions on international collaborations and research in Iran